Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730907 | PMC |
| http://dx.doi.org/10.1038/s41408-023-00963-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Ann Oncol
September 2024
Department of Medicine, Immunology and Allergy Service. Electronic address:
Article Synopsis
- This study evaluated the effectiveness of tocilizumab (TCZ) for treating arthritis caused by immune checkpoint inhibitors (ICI-AR) and preventing relapses during ICI treatment reassignment.
- Researchers analyzed data from 26 patients, finding that all patients treated with TCZ had significant improvement in their arthritis symptoms and many achieved remission without steroids after 24 weeks.
- The results indicated that using TCZ as a preventive measure during ICI rechallenge significantly reduced relapse rates and extended ICI treatment duration compared to patients not receiving TCZ.
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Transplant Cell Ther
November 2024
Stanford University School of Medicine, Stanford, California.
Article Synopsis
- - Axicabtagene ciloleucel (axi-cel) is an approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma, but it often causes side effects like cytokine release syndrome (CRS) and neurological events (NEs).
- - To investigate ways to reduce these toxicities, the ZUMA-1 trial included a safety cohort (Cohort 3) that used the drug tocilizumab and anticonvulsant levetiracetam as preventive measures during treatment.
- - In a 24-month follow-up of 42 patients in Cohort 3, 92% experienced any-grade CRS and 87% had NEs, while the overall response rate was 63
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.
Hemasphere
July 2024
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Leuk Lymphoma
September 2024
Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA, USA.
AMG 330, a bispecific T-cell engager (BiTE®) that binds CD33 and CD3 on T cells facilitates T-cell-mediated cytotoxicity against CD33+ cells. This first-in-human, open-label, dose-escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMG 330 in adults with relapsed/refractory acute myeloid leukemia (R/R AML). Amongst 77 patients treated with AMG 330 (0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!